Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KW-026
- Development stage
- Preclinical
- Lead developer
- Kawin Technology
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
KW-026 is an investigational small interfering RNA (siRNA) therapeutic being developed by Kawin Technology for the treatment of chronic Hepatitis B virus (HBV) infection. As an siRNA-based therapy, it is designed to utilize the endogenous RNA interference (RNAi) pathway to target and degrade specific viral RNA transcripts. This silencing of viral gene expression leads to a reduction in the production of essential viral proteins, such as the Hepatitis B surface antigen (HBsAg), and suppresses viral replication. The primary goal of KW-026 is to lower the viral burden and potentially restore the host's immune response, contributing to the effort to achieve a functional cure for patients with chronic HBV.
- Other names
- KW-026 siRNAKW026 siRNAKW 026 siRNA
02
Targets
HBV RNA (Hepatitis B virus RNA)
Beyond the preview
Go deeper on KW-026.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KW-026.